Boothbay Fund Management, LLC Apellis Pharmaceuticals, Inc. Call Options Transaction History

Boothbay Fund Management, LLC

  • $3.6 Billion
  • Q3 2024

Call Options

11 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$28.84 - $41.15 $1.27 Million - $1.81 Million
44,000 New
44,000 $1.27 Million
Q4 2023

Feb 14, 2024
BUY
$37.14 - $64.82 $1.22 Million - $2.13 Million
32,800 Added 68.91%
80,400 $4.81 Million
Q3 2023

Nov 14, 2023
BUY
$23.65 - $89.22 $1.13 Million - $4.25 Million
47,600 New
47,600 $1.81 Million
Q1 2023

May 15, 2023
BUY
$46.59 - $66.96 $1.74 Million - $2.5 Million
37,300 Added 53.44%
107,100 $7.06 Million
Q4 2022

Feb 14, 2023
BUY
$43.24 - $61.04 $1.51 Million - $2.14 Million
35,000 Added 100.57%
69,800 $3.61 Million
Q3 2022

Nov 14, 2022
BUY
$44.76 - $69.66 $313,320 - $487,620
7,000 Added 25.18%
34,800 $2.38 Million
Q2 2022

Aug 15, 2022
SELL
$35.07 - $59.21 $196,392 - $331,576
-5,600 Reduced 16.77%
27,800 $1.26 Million
Q1 2022

May 16, 2022
BUY
$35.46 - $54.12 $404,244 - $616,968
11,400 Added 51.82%
33,400 $1.7 Million
Q4 2021

Feb 14, 2022
SELL
$30.74 - $49.16 $46,110 - $73,740
-1,500 Reduced 6.38%
22,000 $1.04 Million
Q3 2021

Nov 15, 2021
SELL
$31.4 - $69.84 $332,840 - $740,304
-10,600 Reduced 31.09%
23,500 $775,000
Q2 2021

Aug 16, 2021
BUY
$40.9 - $64.9 $1.39 Million - $2.21 Million
34,100 New
34,100 $2.16 Million

Others Institutions Holding APLS

# of Institutions
308
Shares Held
115M
Call Options Held
3.85M
Put Options Held
1.09M
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.64B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email